Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2341 AL 2355

New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease

Ouyang Q, Meng Y, Zhou W, Tong J, Cheng Z, Zhu Q.

J Drug Target. 2022 Jan;30(1):61-81. doi: 10.1080/1061186X.2021.1927055. Epub 2021 May 20.

Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)

Ferreira JPS, Albuquerque HMT, Cardoso SM, Silva AMS, Silva VLM.

Eur J Med Chem. 2021 Oct 5;221:113492. doi: 10.1016/j.ejmech.2021.113492. Epub 2021 Apr 24.

Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies

Annadurai N, De Sanctis JB, Hajdúch M, Das V.

Exp Neurol. 2021 Sep;343:113756. doi: 10.1016/j.expneurol.2021.113756. Epub 2021 May 12.

Role of γ-Secretase Inhibitors for the Treatment of Diverse Disease Conditions through Inhibition of Notch Signaling Pathway

Mondal A, Bose S, Banerjee S, Pal D.

Curr Drug Targets. 2021;22(15):1799-1807. doi: 10.2174/1389450122666210515161312.

Alzheimer's Disease: Innovative Therapeutic Approaches Based on Peptides and Nanoparticles

Mota IFL, de Lima LS, Santana BM, Gobbo GAM, Bicca JVML, Azevedo JRM, Veras LG, Taveira RAA, Pinheiro GB, Mortari MR.

Neuroscientist. 2023 Feb;29(1):78-96. doi: 10.1177/10738584211016409. Epub 2021 May 21.

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia

Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B.

Cochrane Database Syst Rev. 2021 May 24;5(5):CD004034. doi: 10.1002/14651858.CD004034.pub4.

Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives

Fasae KD, Abolaji AO, Faloye TR, Odunsi AY, Oyetayo BO, Enya JI, Rotimi JA, Akinyemi RO, Whitworth AJ, Aschner M.

J Trace Elem Med Biol. 2021 Sep;67:126779. doi: 10.1016/j.jtemb.2021.126779. Epub 2021 May 15.

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease

Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P; REVERSE-SD Study Investigators.

Alzheimers Res Ther. 2021 May 27;13(1):106. doi: 10.1186/s13195-021-00843-2.

Adiponectin: a potential target for obesity-associated Alzheimer's disease

Samant NP, Gupta GL.

Metab Brain Dis. 2021 Oct;36(7):1565-1572. doi: 10.1007/s11011-021-00756-x. Epub 2021 May 28.

Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease

Jia J, Xu J, Liu J, Wang Y, Wang Y, Cao Y, Guo Q, Qu Q, Wei C, Wei W, Zhang J, Yu E.

Neurosci Bull. 2021 Jul;37(7):1025-1038. doi: 10.1007/s12264-021-00701-z. Epub 2021 May 29.

Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease

Richard E, den Brok MGHE, van Gool WA.

Alzheimers Dement. 2021 Jun;17(6):1051-1055. doi: 10.1002/alz.12379. Epub 2021 May 31.

Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?

Merighi S, Poloni TE, Terrazzan A, Moretti E, Gessi S, Ferrari D.

Cells. 2021 May 20;10(5):1267. doi: 10.3390/cells10051267.

Microglia in Aging and Alzheimer's Disease: A Comparative Species Review

Edler MK, Mhatre-Winters I, Richardson JR.

Cells. 2021 May 8;10(5):1138. doi: 10.3390/cells10051138.

Neuroprotective Natural Products for Alzheimer's Disease

Chen X, Drew J, Berney W, Lei W.

Cells. 2021 May 25;10(6):1309. doi: 10.3390/cells10061309.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias